Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
02:20am, Saturday, 17'th Aug 2024
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host di
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
09:29am, Friday, 16'th Aug 2024
On Friday, Incyte Corporation INCY released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituxima
Incyte's blood cancer drug succeeds late-stage trial
07:09pm, Thursday, 15'th Aug 2024
Incyte said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.
FDA approves Incyte's treatment for chronic graft-versus-host disease
03:49pm, Wednesday, 14'th Aug 2024
The U.S. Food and Drug Administration on Wednesday approved drugmaker Incyte Corp's treatment for a type of graft-versus-host disease (GvHD).
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
12:57pm, Tuesday, 30'th Jul 2024
On Tuesday, Incyte Corporation INCY reported second-quarter revenue of $1.04 billion, up from $954.6 million a year ago, beating the consensus of $1.03 billion.
Incyte Corporation (INCY) Q2 2024 Earnings Call Transcript
11:29am, Tuesday, 30'th Jul 2024
Incyte Corporation (NASDAQ:INCY ) Q2 2024 Earnings Conference Call July 30, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Execut
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
11:10am, Tuesday, 30'th Jul 2024
Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.
Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
10:36am, Tuesday, 30'th Jul 2024
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street es
Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates
09:16am, Tuesday, 30'th Jul 2024
Incyte (INCY) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of $0.78. This compares to earnings of $0.99 per share a year ago.
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
11:35am, Wednesday, 24'th Jul 2024
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 23'rd Jul 2024
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INCY or MYGN: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 18'th Jul 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN). But which of these two companies is the best option for th
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
03:06pm, Monday, 15'th Jul 2024
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
06:53am, Tuesday, 09'th Jul 2024
Cathie Wood was the hottest money manager in the game in 2020. Her Ark Invest family of funds offered investors blistering returns on their money.
7 Cheap Biotech Stocks With Major Upside Potential
06:00am, Tuesday, 09'th Jul 2024
Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market valu
